For adults with moderately to severely active ulcerative colitis (UC).
WHY CHOOSE
TREMFYA®?
An important aspect of managing UC is to help visibly improve the lining of your colon and to treat your symptoms— TREMFYA® can help with both.
In clinical trials, patients
received TREMFYA®
intravenously (IV) through a vein
in the arm with
200 mg at weeks
0, 4, and 8, followed by
subcutaneous (SC) injections
under the skin with either
100 mg every 8 weeks or 200 mg
every 4 weeks.
TREMFYA® was also studied in
another trial where patients
received initial doses of SC
injections with
400 mg at weeks
0, 4, and 8.
FAST ACTING
In aN IV induction study,*
Rapid symptom relief at
relief at
4 weeks
Some patients taking TREMFYA® experienced:
·fewer bowel movements
·less rectal bleeding (blood in stool)
Proven results with SC
and IV initial doses
Almost 3X more patients on
TREMFYA®
achieved clinical
remission† at 12 weeks compared to placebo.
Results with SC initial
doses (no IV)‡:
26% of patients taking TREMFYA® vs 7% of patients on placebo achieved clinical remission at 12 weeks taking 400 mg SC initial injections.
Results with IV
initial doses*:
23% of patients taking TREMFYA® vs 8% of patients on placebo achieved clinical remission at 12 weeks taking 200 mg IV initial infusions.
*Results are from a clinical trial of patients with moderately to severely active UC: 421 patients received TREMFYA® 200 mg IV and 280 patients received placebo.
†Clinical remission is based on frequency of bowel movements, fewer bloody stools, and endoscopy results.
‡Results are from a clinical trial of patients with moderately to severely active UC: 265 patients started with TREMFYA® 400 mg SC doses and 130 patients received placebo.
Interested in starting a
treatment without an IV?
LONG LASTING
In aN SC maintenance study of patients who
responded in the IV induction study,*
over 2X more patients on TREMFYA®
achieved clinical remission† at one year:
over 2X more patients on
TREMFYA®
achieved clinical
remission† at one year:
- 50% of patients taking 200 mg SC maintenance injections vs 19% of patients taking placebo
- 45% of patients taking 100 mg SC maintenance injections vs 19% of patients taking placebo
* Results are from patients who achieved clinical response after 12 weeks of TREMFYA® induction and entered the maintenance trial: 190 patients received TREMFYA® 200 mg, 188 patients received TREMFYA® 100 mg, and 190 patients received placebo.
† Clinical remission is based on frequency of bowel movements, fewer bloody stools, and endoscopy results.
AT 2 YEARS
many patients were in
clinical remission*†:
- 52% of patients taking 200 mg SC maintenance injections who received initial IV doses
- 55% of patients taking 100 mg SC maintenance injections who received initial IV doses
* After 1 year, patients and healthcare providers knew that TREMFYA® was used. This may have increased results.
† Clinical remission is based on frequency of bowel movements, fewer bloody stools, and endoscopy results.
Some patients saw
100% VISIBLE HEALING
OF THEIR INTESTINAL LINING
In an sc maintenance study
of patients who responded in the
IV induction study,*
2X more patients on TREMFYA® achieved endoscopic remission at
at one year, which is no visible signs of inflammation on the colon lining during endoscopy:
2X more patients on TREMFYA®
achieved endoscopic remission at one year, which is no visible signs of inflammation on the colon lining during endoscopy:
- 34% of patients taking TREMFYA® 200 mg SC maintenance injections vs 15% placebo
- 35% of patients taking TREMFYA®
100 mg SC maintenance injections vs 15% placebo
Visually assessed areas may not represent remission of the entire colon lining.
See the difference
with endoscopic imagery†:
Before
TREMFYA®
After one year on
TREMFYA®
*Results are from patients who achieved clinical response after 12 weeks of TREMFYA® induction and entered the maintenance trial: 190 patients received TREMFYA® 200 mg, 188 patients received TREMFYA® 100 mg, and 190 patients received placebo.
†The images are of sections of the colon from an actual patient who enrolled in the TREMFYA® UC induction and maintenance studies.
Individual results may vary.
Talk to your healthcare
provider to see if TREMFYA®
is right for you.
TREMFYA®
LEGACY
15+
YEARS
of combined clinical research*
8+
YEARS
on the market across multiple indications
*Based on a clinical trial of TREMFYA®
initiated in 2009.
TREMFYA® Safety Information
TREMFYA® may cause serious side effects, including:
- Serious allergic reactions. Stop using TREMFYA® and get emergency medical help right away if you develop any of the following symptoms of a serious allergic reaction:
- fainting, dizziness, feeling lightheaded (low blood pressure)
- swelling of your face, eyelids, lips, mouth, tongue or throat
- trouble breathing or throat tightness
- chest tightness
- skin rash, hives
- itching
- Infections. TREMFYA® is a medicine that may lower the ability of your immune system to fight infections and may increase your risk of infections. Your healthcare provider should check you for infections and tuberculosis (TB) before starting treatment with TREMFYA® and may treat you for TB before you begin treatment with TREMFYA® if you have a history of TB or have active TB. Your healthcare provider should watch you closely for signs and symptoms of TB during and after treatment with TREMFYA®. Tell your healthcare provider right away if you have an infection or have symptoms of an infection, including:
- fever, sweats, or chills
- cough
- shortness of breath
- blood in your phlegm (mucus)
- muscle aches
- warm, red, or painful skin or sores on your body different from your psoriasis
- weight loss
- diarrhea or stomach pain
- burning when you urinate or urinating more often than normal
- Liver problems. With the treatment of Crohn’s disease or ulcerative colitis, your healthcare provider will do blood tests to check your liver before and during treatment with TREMFYA®. Your healthcare provider may stop treatment with TREMFYA® if you develop liver problems. Tell your healthcare provider right away if you notice any of the following symptoms:
- unexplained rash
- vomiting
- tiredness (fatigue)
- yellowing of the skin or the whites of your eyes
- nausea
- stomach pain (abdominal)
- loss of appetite
- dark urine
These are not all the possible side effects of TREMFYA®.
Please read the Important Safety Information located at the bottom of the screen and the Medication Guide for TREMFYA® to learn more about these and other risks for TREMFYA®. Discuss any questions you have with your doctor.
TREMFYA® may cause serious side effects, including:
- See “What is the most important information I should know about TREMFYA®?”
The most common side effects of TREMFYA® include:
- respiratory tract infections
- joint pain (arthralgia)
- fungal skin infections
- headache
- diarrhea
- feeling very tired (fatigue)
- skin rash (rash)
- herpes simplex infections
- injection site reactions
- stomach flu (gastroenteritis)
- stomach pain
- bronchitis
- fever (pyrexia)
These are not all the possible side effects of TREMFYA®. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
TREMFYA® may cause serious side effects, including:
- Serious allergic reactions. Stop using TREMFYA® and get emergency medical help right away if you develop any of the following symptoms of a serious allergic reaction:
- fainting, dizziness, feeling lightheaded (low blood pressure)
- swelling of your face, eyelids, lips, mouth, tongue or throat
- trouble breathing or throat tightness
- chest tightness
- skin rash, hives
- itching
- Infections. TREMFYA® is a medicine that may lower the ability of your immune system to fight infections and may increase your risk of infections. Your healthcare provider should check you for infections and tuberculosis (TB) before starting treatment with TREMFYA® and may treat you for TB before you begin treatment with TREMFYA® if you have a history of TB or have active TB. Your healthcare provider should watch you closely for signs and symptoms of TB during and after treatment with TREMFYA®. Tell your healthcare provider right away if you have an infection or have symptoms of an infection, including:
- fever, sweats, or chills
- cough
- shortness of breath
- blood in your phlegm (mucus)
- muscle aches
- warm, red, or painful skin or sores on your body different from your psoriasis
- weight loss
- diarrhea or stomach pain
- burning when you urinate or urinating more often than normal
- Liver problems. With the treatment of Crohn’s disease or ulcerative colitis, your healthcare provider will do blood tests to check your liver before and during treatment with TREMFYA®. Your healthcare provider may stop treatment with TREMFYA® if you develop liver problems. Tell your healthcare provider right away if you notice any of the following symptoms:
- unexplained rash
- vomiting
- tiredness (fatigue)
- yellowing of the skin or the whites of your eyes
- nausea
- stomach pain (abdominal)
- loss of appetite
- dark urine
These are not all the possible side effects of TREMFYA®.
Please read the Important Safety Information located at the bottom of the screen and the Medication Guide for TREMFYA® to learn more about these and other risks for TREMFYA®. Discuss any questions you have with your doctor.
TREMFYA® may cause serious side effects, including:
- See “What is the most important information I should know about TREMFYA®?”
The most common side effects of TREMFYA® include:
- respiratory tract infections
- joint pain (arthralgia)
- fungal skin infections
- headache
- diarrhea
- feeling very tired (fatigue)
- skin rash (rash)
- herpes simplex infections
- injection site reactions
- stomach flu (gastroenteritis)
- stomach pain
- bronchitis
- fever (pyrexia)
These are not all the possible side effects of TREMFYA®. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
